All results
8 results for randomized double blind placebo controlled parallel group multicenter study safety
-
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II)
This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing…
- Ages
- 18 Years - N/A
- Sexes
- All
-
IMPALA-2
160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim or placebo for…
- Ages
- 18 Years - N/A
- Sexes
- All
-
REPLENISH
The purpose of this study is to demonstrate the efficacy and safety of secukinumab 300 milligram (mg) and 150 mg administered subcutaneously (s.c.) for 52…
- Ages
- 50 Years - N/A
- Sexes
- All
-
United therapeutics 301
Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of…
- Ages
- 18 Years - N/A
- Sexes
- All
-
ReCePI
The objective of this study is to evaluate the efficacy and safety of RBC transfusion for support of acute anemia in cardiovascular surgery patients based on…
- Ages
- 11 Years - N/A
- Sexes
- All
-
GCAptAIN
This is a phase III study of efficacy and safety of secukinumab versus placebo, in combination with glucocorticoid taper regimen, in patients with giant cell…
- Ages
- 50 Years - N/A
- Sexes
- All
-
Soleno C602
This is a multi-center, multi-period study with an open-label period followed by a double-blind, placebo-controlled, randomized withdrawal period evaluating…
- Ages
- 4 Years - N/A
- Sexes
- All
-
REMODEL II
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS) The study CLOU064C12302 consists of…
- Ages
- 18 Years - 55 Years
- Sexes
- All